Modality
mAb
MOA
PRMT5i
Target
SMN2
Pathway
Notch
IgANNBSCLC
Development Pipeline
Preclinical
Sep 2018
→ Oct 2028
PreclinicalCurrent
NCT05670610
186 pts·SCLC
2018-09→TBD·Completed
NCT05973896
374 pts·NB
2022-09→2028-10·Recruiting
560 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-092.5y awayInterim· NB
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2028-10-09 · 2.5y away
NB
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05670610 | Preclinical | SCLC | Completed | 186 | PANSS |
| NCT05973896 | Preclinical | NB | Recruiting | 374 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 |